Somewhat Favorable News Coverage Somewhat Unlikely to Affect ADMA Biologics (ADMA) Share Price

Press coverage about ADMA Biologics (NASDAQ:ADMA) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ADMA Biologics earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.3128739342236 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several analysts have issued reports on the company. Maxim Group restated a “buy” rating and set a $8.00 price objective (down previously from $13.00) on shares of ADMA Biologics in a report on Monday, December 11th. Raymond James Financial upgraded ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, November 14th.

ADMA Biologics (NASDAQ:ADMA) traded down $0.12 during midday trading on Friday, reaching $3.57. The company’s stock had a trading volume of 199,337 shares, compared to its average volume of 142,019. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. The firm has a market cap of $92.08, a P/E ratio of -4.35 and a beta of 2.50. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $5.74.

In other ADMA Biologics news, insider Adam S. Grossman bought 485,000 shares of the stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $1,042,750.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Eric I. Richman bought 25,000 shares of the stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $2.15 per share, for a total transaction of $53,750.00. Following the purchase, the director now owns 31,300 shares in the company, valued at $67,295. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 526,500 shares of company stock worth $1,131,975. Corporate insiders own 60.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2018/01/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-adma-biologics-adma-share-price.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply